NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ICE Bioscience

ICE Bioscience

Private
BeijingHealthcare & Life Scienceshttps://ice-biosci.com/

Last Round

Series B++

May 14, 2024

Total Funding Raised

$27.9M

Company Overview

ICE Bioscience is a biotechnology company that operates as an integrated drug discovery contract research organization (CRO). The company provides services including target identification and validation, lead compound screening, and pre-clinical candidate selection for pharmaceutical and biotech partners.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

contract research organizationCROdrug discovery servicespreclinical drug discoveryion channel researchin vivo pharmacologyDMPK serviceselectrophysiology servicessafety pharmacologyoutsourced R&Dkinase assayscardiac safety assessmentprotein expressionstable cell line generationAI drug discoveryin silico drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ICE Bioscience Comps

Public and private peers based on sector, stage, and business model.

ICE Bioscience comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

ICE Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B++May 14, 2024
Series B ExtensionAug 1, 2023
Series BSep 26, 2022
Series AMay 14, 2021

Key People

Founding team and executive leadership

li yan

Chairman, CEO

Executive Team

Yingji Li

Chief Executive Officer

Executive Team

ICE Bioscience Investors

Notable investors and investment history

ICE Bioscience investors
InvestorRounds
Alwin CapitalSeries B Extension, Series B++
Beijing E-Town International Investment & Development Co., Ltd.Series B++
Addor CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 17, 2025

    Grew 24% QoQ, from 25 to 31 employees.

  • Nov 27, 2024

    Grew 47% QoQ, from 19 to 28 employees.

ICE Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ICE Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ICE Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range33
Year Founded2010
Last FundingMay 14, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.